It remains a crucial component of the “gold standard” for patients with CLL who are deemed “fit” for full-dose fludarabine, as part of the Fludarabine Cyclophosphamide Rituximab (FCR) regime, and this strategy has yet to be outperformed in terms of OR and OS rates in the frontline setting, although it is not suitable for patients who have a 17p deletion or TP53 mutation [7••]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.